Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers


1. Dcc-3014
2. 1628606-05-2
3. Vimseltinib [inn]
4. Vimseltinib [usan]
5. Px9ftm69bf
6. Dcc3014
7. 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one
8. 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
9. Dp-6865
10. 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinone
11. 4(3h)-pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
12. Unii-px9ftm69bf
13. Vimseltinib [who-dd]
14. Schembl16047448
15. Gtpl11190
16. Ex-a4700
17. Nsc828316
18. Who 11443
19. Nsc-828316
20. Example 10 [wo2014145025a2]
21. Hy-136256
22. Cs-0121044
23. 3-methyl-5-(6-methyl-5-{[2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl]oxy}pyridin-2-yl)-2-[(propan-2-yl)amino]pyrimidin-4(3h)-one
24. Z6v
| Molecular Weight | 431.5 g/mol |
|---|---|
| Molecular Formula | C23H25N7O2 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 431.20697307 g/mol |
| Monoisotopic Mass | 431.20697307 g/mol |
| Topological Polar Surface Area | 97.5 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 740 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Vimseltinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vimseltinib manufacturer or Vimseltinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vimseltinib manufacturer or Vimseltinib supplier.
PharmaCompass also assists you with knowing the Vimseltinib API Price utilized in the formulation of products. Vimseltinib API Price is not always fixed or binding as the Vimseltinib Price is obtained through a variety of data sources. The Vimseltinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vimseltinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vimseltinib, including repackagers and relabelers. The FDA regulates Vimseltinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vimseltinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vimseltinib supplier is an individual or a company that provides Vimseltinib active pharmaceutical ingredient (API) or Vimseltinib finished formulations upon request. The Vimseltinib suppliers may include Vimseltinib API manufacturers, exporters, distributors and traders.
click here to find a list of Vimseltinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vimseltinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vimseltinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vimseltinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vimseltinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vimseltinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vimseltinib suppliers with NDC on PharmaCompass.
Vimseltinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vimseltinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vimseltinib GMP manufacturer or Vimseltinib GMP API supplier for your needs.
A Vimseltinib CoA (Certificate of Analysis) is a formal document that attests to Vimseltinib's compliance with Vimseltinib specifications and serves as a tool for batch-level quality control.
Vimseltinib CoA mostly includes findings from lab analyses of a specific batch. For each Vimseltinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vimseltinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vimseltinib EP), Vimseltinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vimseltinib USP).